Abstract
The treatment of chronic lymphocytic leukemia includes the use of alkylating agents, steroids, and more recently nucleoside analogues. While prior studies have described potential mechanisms of 2-chlorodeoxyadenosine cytotoxicity including the accumulation of DNA strand breaks and induction of apoptosis or programmed cell death, the expression of p53 and its downstream target WAF1/CIP1 have not been examined. In this report we describe the induction of p53 and WAF1/CIP1 in the apoptotic chronic lymphocytic leukemia cells after exposure to 2-chlorodeoxyadenosine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- 2-CDA :
-
2-Chlorodeoxyadenosine
- CLL :
-
Chronic lymphocytic leukemia
References
O'Brien S, del Giglio A, Keating M (1995) Advances in the biology and treatment of B-cell Chronic Lymphocytic Leukemia. Blood 85:307–318
Liepman M, Votaw ML (1978) The treatment of chronic lymphocytic leukemia with COP chemotherapy. Cancer 41:1664–1668
French Cooperative Group on Chronic Lymphocytic Leukemia (1990) A randomized clinical trial of chlorambucil versus COP in Stage B chronic lymphocytic leukemia. Blood 75: 1422–1427
Keating MJ, Estey E, O'Brien S, Kantarjian H, Robertson LE, Plunkett W (1994) Clinical experience with fludarabine in leukemia. Drugs 47:39–44
Tallman M, Hakimian D, Variakojis (1992) A single cycle of 2-chlorodeoxyadenosine in the majority of patients with hairy cell leukemia. Blood 80:2203–2207
Carson DA, Wasson DB, Beutler E (1984) Antileukemia and immunosuppressive activity of 2-CDA. Proc Natl Acad Sci USA 81:2232–2236
Robertson L, Chubb S, Story M (1991) Induction of DNA cleavage in chronic lymphocytic leukemia cells by chlorodeoxydeadenosine and fludarabine. Proc Am Assoc Can Res 32:415
Huang MC, Ashmun RA, Avery TL (1986) Effects of cytotoxicity of 2-choro-2-deoxyadenosine and 2-bromo-2- deoxyadenosine on cell growth, clonogenicity, DNA synthesis and cell cycle kinetics. Cancer Res 46:2362–2368
El-Deiry W, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAFI, a potential mediator of p53 tumor suppression. Cell 75:817–823
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge S (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of GI cyclin dependent kinases. Cell 75:805–812
Lowe SW, Ruley HE, Jacks T, Houseman DE (1993) p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957–962
Cole SP (1986) Rapid chemosensitivity testing of human tumor cells using the MTT assay. Cancer Chemother Pharmacol 17:259–263
Gong J, Traganos F, Darzynkiewiez Z (1994) A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 218: 314–318
Fan S, El Deiry W, Bae I, Freeman J, Jondle D, Bhatia K, Fornace Jr. AJ, Magrath I, Kohn KW, O'Connor PM (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54:5824–5828
Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D (1994) Induction of WAF1/CIP1 by a p53 independent pathway. Cancer Res 54:3391–3396
Fenaux P, Preudhomme C, Lai JL, Quiquandon I, Jonvenux H, Vanrumbeke M, Sartiaux C, Morel P, LeFebevre MHL, Bauters F, Berger R, Kerckaert JP (1992) Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: A report on 39 cases with cytogenetic analysis. Leukemia 6:246–250
Gaidano G, Ballerini P, Gong J, Inghirami G, Neri A, Newcomb E, Magrath I, Knowles D, Dalla Favera R (1991) p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413–5418
Linzer DH, Levine AJ (1979) Characterization of a 54 kd cellular Sv-40 tumor antigen in Sv-40 transformed cells. Cell 17:43–50
Sarnow P, Ho YS, Williams J, Levine AJ (1982) Adenovirus Elb-58 kd tumor antigen and Sv-40 large antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28:387–393
Gartenhaus RB, Wang P, Hoffmann P. Induction of WAF1/CIP1 and apoptosis in HTLV-I transformed lymphocytes after treatment with Adriamycin using a p53 independent pathway. Proc Natl Acad Sci USA (in press)
Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD (1991) 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leukoc Lymphoma 5:133
Saven A, Lemon RH, Kosty M, Beutler E, Piro LD (1993) 2-Chlorodeoxyadenosine activity in patients with previously untreated chronic lymphocytic leukemia. Blood 82:445a
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 6:219–234
Dohner H, Fischer K, Benta M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy, Stilgenbauer S, Volkmann M, Galle PR, Poustka A, Hunstein W, Lichter P (1995) p53 gene deletion predicts for poor survival and non response to therapy with purine analogs in chronic B-CLL leukemias. Blood 85:1580–1589
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gartenhaus, R.B., Wang, P., Hoffman, M. et al. The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine. J Mol Med 74, 143–147 (1996). https://doi.org/10.1007/BF01575446
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01575446